We hope all our readers had an excellent holiday-of-your-choice. We did, and we’re back just in time for our favorite (and nearly last) post of the year, our choices for the best prescription medical product liability decisions of 2012. This time, we have to admit, there’s no obvious winner, since the year passed without a
2012
Anti-Bartlett Arguments
…
And Now For A Word From The Grinch
This post is contributed by Melissa Wojtylak, of ReedSmith, one of our regular guest bloggers whom we’re trying to convince to join us on a more formal basis. Take it away Melissa:
******************
The Southern District of Illinois delivered a giant lump
of coal when it denied the defendant’s motion for summary judgment in a…
Preemption Wonderland
For the holidays, we have for you the story of Littlebear v. Advanced Bionics, LLC, 2012 U.S. Dist. LEXIS 179388 (N.D. Ok. Dec. 19, 2012). The story is to be sung, of course, to the tune of Winter Wonderland. Enjoy boys and girls.
Preemption Wonderland
Sleigh bells ring, Buckman Preemption,
In the lane, PMA…
Buried Treasure
…
The Bottom Ten – The Worst Prescription Drug/Medical Device Decisions Of 2012
Do we have to? That depends on whether we mean “must” or should.” There’s relatively little that’s really a “must,” but quite a bit that’s a strong “should.” So yes, we have to. It’s that time of year again, and we’re looking back over the past twelve months for the decisions that, in this instance,…
What We Like To See From A To Z
We appreciate being on Joe Hollingsworth’s mailing list – we really do. Much of the Aredia/Zometa stuff he sends us is manifestly blogworthy. That, and all things being equal, we’d rather discuss a defense win than a defense loss. Joe doesn’t send us his bad ones (although certain plaintiff lawyers do pass…
At Risk Claims Sufficient To Support Federal CAFA Jurisdiction
Back when Bexis was still at Dechert, we put up a cautionary post called “CAFA Not With Standing.” In that post we cautioned against using constitutional standing as a defense to class actions with questionable and attenuated damages claims. Remember CAFA, we pointed out. The damages sought in state-court class actions need to support federal Article III standing, or else defendants won’t be able to keep the actions in federal court.
Well, yesterday the court in Bouldry v. C.R. Bard, Inc., No. 12-80951-CIV, slip op. (S.D. Fla. Dec. 18, 2012), addressed precisely the situation discussed in that post. Fortunately, our side won, and the class action stayed in federal court, where there are plenty of other arguments against its validity.
First, we have to point out that Reed Smith was involved in the Bouldry case, so we can’t say as much as we’d like. We’ll have to stick to the legal propositions. As for the facts, all we can say is that the Bouldry opinion should be applicable to other attenuated injury class actions, regardless of the product or conduct involved.
Bouldry involved a state class action in Florida alleging that a medical device had a higher risk of failure than it should. The class consisted of people who had not suffered any failure. There are good arguments that this sort of at-risk damages are not recoverable under most states’ laws − see our no injury scorecard, and in particular the Shiley heart valve cases from the late 1980s and early 1990s, which addressed similar allegations. Hint: the defendant won almost all of them.Continue Reading At Risk Claims Sufficient To Support Federal CAFA Jurisdiction
Minnesota Musings on Primary Jurisdiction and the Platonic Ideal of Greek Yogurt
…
Shout Outs
Our thanks go to the following readers for the following reasons.
First, to Glenn Lammi over at the Washington Legal Foundation, who in response to our Caronia Roundup, pointed out that WLF was having a Web Seminar
on the subject. Unfortunately, it was today. Too bad we didn’t get around to posting this…